Asakura Junko, Nagao Manabu, Shinohara Masakazu, Hosooka Tetsuya, Kuwahara Naoya, Nishimori Makoto, Tanaka Hidekazu, Satomi-Kobayashi Seimi, Matsui Sho, Sasaki Tsutomu, Kitamura Tadahiro, Otake Hiromasa, Ishida Tatsuro, Ogawa Wataru, Hirata Ken-Ichi, Toh Ryuji
Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Division of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Cardiovasc Diabetol. 2025 Apr 16;24(1):167. doi: 10.1186/s12933-025-02725-5.
Systemic insulin resistance plays an important role in the pathogenesis of type 2 diabetes and its complications. Although impaired branched-chain amino acid (BCAA) metabolism has been reported to be involved in the development of diabetes, the relationship between cardiac BCAA metabolism and the pathogenesis of diabetic cardiomyopathy (DbCM) remains unclear.
The aim of this study was to investigate BCAA metabolism in insulin-resistant hearts by using a novel mouse model of DbCM.
The cardiac phenotypes of adipocyte-specific 3'-phosphoinositide-dependent kinase 1 (PDK1)-deficient (A-PDK1KO) mice were assessed by histological analysis and echocardiography. The metabolic characteristics and cardiac gene expression were determined by mass spectrometry or RNA sequencing, respectively. Cardiac protein expression was evaluated by Western blot analysis.
A-PDK1KO mouse hearts exhibited hypertrophy with prominent insulin resistance, consistent with cardiac phenotypes and metabolic disturbances previously reported as DbCM characteristics. RNA sequencing revealed the activation of BCAA uptake in diabetic hearts. In addition, the key enzymes involved in cardiac BCAA catabolism were downregulated at the protein level in A-PDK1KO mice, leading to the accumulation of BCAAs in the heart. Mechanistically, the accumulation of the BCAA leucine caused cardiac hypertrophy via the activation of mammalian target of rapamycin complex 1 (mTORC1).
A-PDK1KO mice closely mimic the cardiac phenotypes and metabolic alterations observed in human DbCM and exhibit impaired BCAA metabolism in the heart. This model may contribute to a better understanding of DbCM pathophysiology and to the development of novel therapies for this disease.
全身性胰岛素抵抗在2型糖尿病及其并发症的发病机制中起重要作用。尽管已有报道称支链氨基酸(BCAA)代谢受损与糖尿病的发生有关,但心脏BCAA代谢与糖尿病性心肌病(DbCM)发病机制之间的关系仍不清楚。
本研究旨在通过使用一种新型的DbCM小鼠模型来研究胰岛素抵抗心脏中的BCAA代谢。
通过组织学分析和超声心动图评估脂肪细胞特异性3'-磷酸肌醇依赖性激酶1(PDK1)缺陷(A-PDK1KO)小鼠的心脏表型。分别通过质谱或RNA测序确定代谢特征和心脏基因表达。通过蛋白质印迹分析评估心脏蛋白表达。
A-PDK1KO小鼠心脏表现出肥大并伴有明显的胰岛素抵抗,这与先前报道的作为DbCM特征的心脏表型和代谢紊乱一致。RNA测序显示糖尿病心脏中BCAA摄取的激活。此外,A-PDK1KO小鼠心脏中参与BCAA分解代谢的关键酶在蛋白质水平上被下调,导致BCAAs在心脏中积累。从机制上讲,BCAA亮氨酸的积累通过激活雷帕霉素复合物1(mTORC1)的哺乳动物靶点导致心脏肥大。
A-PDK1KO小鼠紧密模拟了人类DbCM中观察到的心脏表型和代谢改变,并在心脏中表现出BCAA代谢受损。该模型可能有助于更好地理解DbCM的病理生理学,并有助于开发针对该疾病的新疗法。